 | • レポートコード：20QY06-00256 • 出版社/出版日：QYResearch / 2020年6月1日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、142ページ • 納品方法：Eメール（受注後2~3営業日） • 産業分類：医薬品・医療 |
| Single User | ￥592,000 (USD4,000) | ▷ お問い合わせ |
| Multi User | ￥888,000 (USD6,000) | ▷ お問い合わせ |
| Enterprise License | ￥1,184,000 (USD8,000) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社の当調査資料では、ENG（エンドグリン前駆体）のグローバル市場について種類別（90％以上、95％以上、99％以上、その他）、用途別（バイオ製薬会社、病院、バイオサイエンス研究機関、その他）、地域別（北米、ヨーロッパ、中国、日本、東南アジア、インド）に区分して調査し、纏めました。2015年～2026年までの市場規模予測、主要プレイヤーの競争状況・市場シェア・企業情報、製造コスト分析、販売チャネル・流通業者・顧客情報、市場動向・機会・課題などのマーケットデータが記載されています。 ・ENG（エンドグリン前駆体）市場の概要 ・世界の主要地域別ENG（エンドグリン前駆体）市場規模2015-2026 ・主要プレイヤーの競争状況・市場シェア ・世界のENG（エンドグリン前駆体）市場規模2015-2026：種類別（90％以上、95％以上、99％以上、その他） ・世界のENG（エンドグリン前駆体）市場規模2015-2026：用途別（バイオ製薬会社、病院、バイオサイエンス研究機関、その他） ・ENG（エンドグリン前駆体）の北米市場規模2015-2020 ・ENG（エンドグリン前駆体）のヨーロッパ市場規模2015-2020 ・ENG（エンドグリン前駆体）の中国市場規模2015-2020 ・ENG（エンドグリン前駆体）の日本市場規模2015-2020 ・ENG（エンドグリン前駆体）の東南アジア市場規模2015-2020 ・ENG（エンドグリン前駆体）のインド市場規模2015-2020 ・主要プレイヤーの企業情報：事業概要・売上・企業動向 （Aviva Systems Biology Corporation(USA)、Atlas Antibodies(Sweden)、Abbexa Ltd(UK)、Abiocode(US)、Boster Biological Technology(USA)、Biobyt(UK)、Bio-Rad(US)、Bioss Antibodies(US)、Biosensis(US)、BioLegend(US)、BioVision(US)、BethylLaboratories(US)、Epigentek(US)、EnzoLifeSciences(Switzerland)、Genetex(US)、Lifespan Biosciences(US)、Novus Biologicals(US)、Proteintech(US)、ProSci(US)、ProteoGenix(France)、R&D Systems(US)、Rockland(US)、St John's Laboratory Ltd(UK)、Stemcell(Canada)、Thermo Fisher Scientific(US)、USBiological(US)） ・ENG（エンドグリン前駆体）の製造コスト分析 ・販売チャネル、流通業者、顧客 ・ENG（エンドグリン前駆体）の市場動向・機会・課題 ・調査の結論 |
Market Analysis and Insights: Global ENG(Endoglin precursor) Market
The global ENG(Endoglin precursor) market was valued at US$ xx million in 2019 and will reach US$ xx million by the end of 2026, growing at a CAGR of xx% during 2020-2026.
Global ENG(Endoglin precursor) Scope and Market Size
The global ENG(Endoglin precursor) market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global ENG(Endoglin precursor) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the ENG(Endoglin precursor) market is segmented into
Above 90%
Above 95%
Above 99%
Others
Segment by Application, the ENG(Endoglin precursor) market is segmented into
Biopharmaceutical Companies
Hospitals
Bioscience Research Institutions
Others
The ENG(Endoglin precursor) market is analysed and market size information is provided by regions (countries). Segment by Application, the ENG(Endoglin precursor) market is segmented into United States, Europe, China, Japan, Southeast Asia, India and Rest of World.
The report includes region-wise market size for the period 2015-2026. It also includes market size and forecast by players, by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and ENG(Endoglin precursor) Market Share Analysis
ENG(Endoglin precursor) market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in ENG(Endoglin precursor) business, the date to enter into the ENG(Endoglin precursor) market, ENG(Endoglin precursor) product introduction, recent developments, etc.
The major vendors covered:
Aviva Systems Biology Corporation(USA)
Atlas Antibodies(Sweden)
Abbexa Ltd(UK)
Abiocode(US)
Boster Biological Technology(USA)
Biobyt(UK)
Bio-Rad(US)
Bioss Antibodies(US)
Biosensis(US)
BioLegend(US)
BioVision(US)
BethylLaboratories(US)
Epigentek(US)
EnzoLifeSciences(Switzerland)
Genetex(US)
Lifespan Biosciences(US)
Novus Biologicals(US)
Proteintech(US)
ProSci(US)
ProteoGenix(France)
R&D Systems(US)
Rockland(US)
St John’s Laboratory Ltd(UK)
Stemcell(Canada)
Thermo Fisher Scientific(US)
USBiological(US)
Table of Contents
1 ENG(Endoglin precursor) Market Overview
1.1 ENG(Endoglin precursor) Product Scope
1.2 ENG(Endoglin precursor) Segment by Type
1.2.1 Global ENG(Endoglin precursor) Sales by Type (2020-2026)
1.2.2 Above 90%
1.2.3 Above 95%
1.2.4 Above 99%
1.2.5 Others
1.3 ENG(Endoglin precursor) Segment by Application
1.3.1 Global ENG(Endoglin precursor) Sales Comparison by Application (2020-2026)
1.3.2 Biopharmaceutical Companies
1.3.3 Hospitals
1.3.4 Bioscience Research Institutions
1.3.5 Others
1.4 ENG(Endoglin precursor) Market Estimates and Forecasts (2015-2026)
1.4.1 Global ENG(Endoglin precursor) Sales Growth Rate (2015-2026)
1.4.2 Global ENG(Endoglin precursor) Revenue and Growth Rate (2015-2026)
1.4.3 Global ENG(Endoglin precursor) Price Trends (2015-2026)
2 ENG(Endoglin precursor) Estimate and Forecast by Region
2.1 Global ENG(Endoglin precursor) Market Size by Region: 2015 VS 2020 VS 2026
2.2 Global ENG(Endoglin precursor) Retrospective Market Scenario by Region (2015-2020)
2.2.1 Global ENG(Endoglin precursor) Sales Market Share by Region (2015-2020)
2.2.2 Global ENG(Endoglin precursor) Revenue Market Share by Region (2015-2020)
2.3 Global ENG(Endoglin precursor) Market Estimates and Forecasts by Region (2021-2026)
2.3.1 Global ENG(Endoglin precursor) Sales Estimates and Forecasts by Region (2021-2026)
2.3.2 Global ENG(Endoglin precursor) Revenue Forecast by Region (2021-2026)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 United States ENG(Endoglin precursor) Estimates and Projections (2015-2026)
2.4.2 Europe ENG(Endoglin precursor) Estimates and Projections (2015-2026)
2.4.3 China ENG(Endoglin precursor) Estimates and Projections (2015-2026)
2.4.4 Japan ENG(Endoglin precursor) Estimates and Projections (2015-2026)
2.4.5 Southeast Asia ENG(Endoglin precursor) Estimates and Projections (2015-2026)
2.4.6 India ENG(Endoglin precursor) Estimates and Projections (2015-2026)
3 Global ENG(Endoglin precursor) Competition Landscape by Players
3.1 Global Top ENG(Endoglin precursor) Players by Sales (2015-2020)
3.2 Global Top ENG(Endoglin precursor) Players by Revenue (2015-2020)
3.3 Global ENG(Endoglin precursor) Market Share by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in ENG(Endoglin precursor) as of 2019)
3.4 Global ENG(Endoglin precursor) Average Price by Company (2015-2020)
3.5 Manufacturers ENG(Endoglin precursor) Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3.7 Primary Interviews with Key ENG(Endoglin precursor) Players (Opinion Leaders)
4 Global ENG(Endoglin precursor) Market Size by Type
4.1 Global ENG(Endoglin precursor) Historic Market Review by Type (2015-2020)
4.1.1 Global ENG(Endoglin precursor) Sales Market Share by Type (2015-2020)
4.1.2 Global ENG(Endoglin precursor) Revenue Market Share by Type (2015-2020)
4.1.3 Global ENG(Endoglin precursor) Price by Type (2014-2020)
4.2 Global ENG(Endoglin precursor) Market Estimates and Forecasts by Type (2021-2026)
4.2.1 Global ENG(Endoglin precursor) Sales Forecast by Type (2021-2026)
4.2.2 Global ENG(Endoglin precursor) Revenue Forecast by Type (2021-2026)
4.2.3 Global ENG(Endoglin precursor) Price Forecast by Type (2021-2026)
5 Global ENG(Endoglin precursor) Market Size by Application
5.1 Global ENG(Endoglin precursor) Historic Market Review by Application (2015-2020)
5.1.1 Global ENG(Endoglin precursor) Sales Market Share by Application (2015-2020)
5.1.2 Global ENG(Endoglin precursor) Revenue Market Share by Application (2015-2020)
5.1.3 Global ENG(Endoglin precursor) Price by Application (2015-2020)
5.2 Global ENG(Endoglin precursor) Market Estimates and Forecasts by Application (2021-2026)
5.2.1 Global ENG(Endoglin precursor) Sales Forecast by Application (2021-2026)
5.2.2 Global ENG(Endoglin precursor) Revenue Forecast by Application (2021-2026)
5.2.3 Global ENG(Endoglin precursor) Price Forecast by Application (2021-2026)
3 North America ENG(Endoglin precursor) Market Facts & Figures
3.2 North America ENG(Endoglin precursor) Sales Market Share by Company (2015-2020)
3.3 North America ENG(Endoglin precursor) Sales Market Share by Type (2015-2020)
3.4 North America ENG(Endoglin precursor) Sales Market Share by Application (2015-2020)
4 Europe ENG(Endoglin precursor) Market Facts & Figures
4.2 Europe ENG(Endoglin precursor) Sales Market Share by Company (2015-2020)
4.3 Europe ENG(Endoglin precursor) Sales Market Share by Type (2015-2020)
4.4 Europe ENG(Endoglin precursor) Sales Market Share by Application (2015-2020)
5 China ENG(Endoglin precursor) Market Facts & Figures
5.2 China ENG(Endoglin precursor) Sales Market Share by Company (2015-2020)
5.3 China ENG(Endoglin precursor) Sales Market Share by Type (2015-2020)
5.4 China ENG(Endoglin precursor) Sales Market Share by Application (2015-2020)
6 Japan ENG(Endoglin precursor) Market Facts & Figures
6.2 Japan ENG(Endoglin precursor) Sales Market Share by Company (2015-2020)
6.3 Japan ENG(Endoglin precursor) Sales Market Share by Type (2015-2020)
6.4 Japan ENG(Endoglin precursor) Sales Market Share by Application (2015-2020)
7 Southeast Asia ENG(Endoglin precursor) Market Facts & Figures
7.2 Southeast Asia ENG(Endoglin precursor) Sales Market Share by Company (2015-2020)
7.3 Southeast Asia ENG(Endoglin precursor) Sales Market Share by Type (2015-2020)
7.4 Southeast Asia ENG(Endoglin precursor) Sales Market Share by Application (2015-2020)
8 India ENG(Endoglin precursor) Market Facts & Figures
8.2 India ENG(Endoglin precursor) Sales Market Share by Company (2015-2020)
8.3 India ENG(Endoglin precursor) Sales Market Share by Type (2015-2020)
8.4 India ENG(Endoglin precursor) Sales Market Share by Application (2015-2020)
12 Company Profiles and Key Figures in ENG(Endoglin precursor) Business
12.1 Aviva Systems Biology Corporation(USA)
12.1.1 Aviva Systems Biology Corporation(USA) ENG(Endoglin precursor) Corporation Information
12.1.2 Aviva Systems Biology Corporation(USA) ENG(Endoglin precursor) Business Overview and Total Revenue
12.1.3 Aviva Systems Biology Corporation(USA) ENG(Endoglin precursor) Sales, Revenue and Gross Margin (2015-2020)
12.1.4 Aviva Systems Biology Corporation(USA) ENG(Endoglin precursor) Products Offered
12.1.5 Aviva Systems Biology Corporation(USA) Recent Development
12.2 Atlas Antibodies(Sweden)
12.2.1 Atlas Antibodies(Sweden) ENG(Endoglin precursor) Corporation Information
12.2.2 Atlas Antibodies(Sweden) ENG(Endoglin precursor) Business Overview and Total Revenue
12.2.3 Atlas Antibodies(Sweden) ENG(Endoglin precursor) Sales, Revenue and Gross Margin (2015-2020)
12.2.4 Atlas Antibodies(Sweden) ENG(Endoglin precursor) Products Offered
12.2.5 Atlas Antibodies(Sweden) Recent Development
12.3 Abbexa Ltd(UK)
12.3.1 Abbexa Ltd(UK) ENG(Endoglin precursor) Corporation Information
12.3.2 Abbexa Ltd(UK) ENG(Endoglin precursor) Business Overview and Total Revenue
12.3.3 Abbexa Ltd(UK) ENG(Endoglin precursor) Sales, Revenue and Gross Margin (2015-2020)
12.3.4 Abbexa Ltd(UK) ENG(Endoglin precursor) Products Offered
12.3.5 Abbexa Ltd(UK) Recent Development
12.4 Abiocode(US)
12.4.1 Abiocode(US) ENG(Endoglin precursor) Corporation Information
12.4.2 Abiocode(US) ENG(Endoglin precursor) Business Overview and Total Revenue
12.4.3 Abiocode(US) ENG(Endoglin precursor) Sales, Revenue and Gross Margin (2015-2020)
12.4.4 Abiocode(US) ENG(Endoglin precursor) Products Offered
12.4.5 Abiocode(US) Recent Development
12.5 Boster Biological Technology(USA)
12.5.1 Boster Biological Technology(USA) ENG(Endoglin precursor) Corporation Information
12.5.2 Boster Biological Technology(USA) ENG(Endoglin precursor) Business Overview and Total Revenue
12.5.3 Boster Biological Technology(USA) ENG(Endoglin precursor) Sales, Revenue and Gross Margin (2015-2020)
12.5.4 Boster Biological Technology(USA) ENG(Endoglin precursor) Products Offered
12.5.5 Boster Biological Technology(USA) Recent Development
12.6 Biobyt(UK)
12.6.1 Biobyt(UK) ENG(Endoglin precursor) Corporation Information
12.6.2 Biobyt(UK) ENG(Endoglin precursor) Business Overview and Total Revenue
12.6.3 Biobyt(UK) ENG(Endoglin precursor) Sales, Revenue and Gross Margin (2015-2020)
12.6.4 Biobyt(UK) ENG(Endoglin precursor) Products Offered
12.6.5 Biobyt(UK) Recent Development
12.7 Bio-Rad(US)
12.7.1 Bio-Rad(US) ENG(Endoglin precursor) Corporation Information
12.7.2 Bio-Rad(US) ENG(Endoglin precursor) Business Overview and Total Revenue
12.7.3 Bio-Rad(US) ENG(Endoglin precursor) Sales, Revenue and Gross Margin (2015-2020)
12.7.4 Bio-Rad(US) ENG(Endoglin precursor) Products Offered
12.7.5 Bio-Rad(US) Recent Development
12.8 Bioss Antibodies(US)
12.8.1 Bioss Antibodies(US) ENG(Endoglin precursor) Corporation Information
12.8.2 Bioss Antibodies(US) ENG(Endoglin precursor) Business Overview and Total Revenue
12.8.3 Bioss Antibodies(US) ENG(Endoglin precursor) Sales, Revenue and Gross Margin (2015-2020)
12.8.4 Bioss Antibodies(US) ENG(Endoglin precursor) Products Offered
12.8.5 Bioss Antibodies(US) Recent Development
12.9 Biosensis(US)
12.9.1 Biosensis(US) ENG(Endoglin precursor) Corporation Information
12.9.2 Biosensis(US) ENG(Endoglin precursor) Business Overview and Total Revenue
12.9.3 Biosensis(US) ENG(Endoglin precursor) Sales, Revenue and Gross Margin (2015-2020)
12.9.4 Biosensis(US) ENG(Endoglin precursor) Products Offered
12.9.5 Biosensis(US) Recent Development
12.10 BioLegend(US)
12.10.1 BioLegend(US) ENG(Endoglin precursor) Corporation Information
12.10.2 BioLegend(US) ENG(Endoglin precursor) Business Overview and Total Revenue
12.10.3 BioLegend(US) ENG(Endoglin precursor) Sales, Revenue and Gross Margin (2015-2020)
12.10.4 BioLegend(US) ENG(Endoglin precursor) Products Offered
12.10.5 BioLegend(US) Recent Development
12.11 BioVision(US)
12.11.1 BioVision(US) ENG(Endoglin precursor) Corporation Information
12.11.2 BioVision(US) ENG(Endoglin precursor) Business Overview and Total Revenue
12.11.3 BioVision(US) ENG(Endoglin precursor) Sales, Revenue and Gross Margin (2015-2020)
12.11.4 BioVision(US) ENG(Endoglin precursor) Products Offered
12.11.5 BioVision(US) Recent Development
12.12 BethylLaboratories(US)
12.12.1 BethylLaboratories(US) ENG(Endoglin precursor) Corporation Information
12.12.2 BethylLaboratories(US) ENG(Endoglin precursor) Business Overview and Total Revenue
12.12.3 BethylLaboratories(US) ENG(Endoglin precursor) Sales, Revenue and Gross Margin (2015-2020)
12.12.4 BethylLaboratories(US) ENG(Endoglin precursor) Products Offered
12.12.5 BethylLaboratories(US) Recent Development
12.13 Epigentek(US)
12.13.1 Epigentek(US) ENG(Endoglin precursor) Corporation Information
12.13.2 Epigentek(US) ENG(Endoglin precursor) Business Overview and Total Revenue
12.13.3 Epigentek(US) ENG(Endoglin precursor) Sales, Revenue and Gross Margin (2015-2020)
12.13.4 Epigentek(US) ENG(Endoglin precursor) Products Offered
12.13.5 Epigentek(US) Recent Development
12.14 EnzoLifeSciences(Switzerland)
12.14.1 EnzoLifeSciences(Switzerland) ENG(Endoglin precursor) Corporation Information
12.14.2 EnzoLifeSciences(Switzerland) ENG(Endoglin precursor) Business Overview and Total Revenue
12.14.3 EnzoLifeSciences(Switzerland) ENG(Endoglin precursor) Sales, Revenue and Gross Margin (2015-2020)
12.14.4 EnzoLifeSciences(Switzerland) ENG(Endoglin precursor) Products Offered
12.14.5 EnzoLifeSciences(Switzerland) Recent Development
12.15 Genetex(US)
12.15.1 Genetex(US) ENG(Endoglin precursor) Corporation Information
12.15.2 Genetex(US) ENG(Endoglin precursor) Business Overview and Total Revenue
12.15.3 Genetex(US) ENG(Endoglin precursor) Sales, Revenue and Gross Margin (2015-2020)
12.15.4 Genetex(US) ENG(Endoglin precursor) Products Offered
12.15.5 Genetex(US) Recent Development
12.16 Lifespan Biosciences(US)
12.16.1 Lifespan Biosciences(US) ENG(Endoglin precursor) Corporation Information
12.16.2 Lifespan Biosciences(US) ENG(Endoglin precursor) Business Overview and Total Revenue
12.16.3 Lifespan Biosciences(US) ENG(Endoglin precursor) Sales, Revenue and Gross Margin (2015-2020)
12.16.4 Lifespan Biosciences(US) ENG(Endoglin precursor) Products Offered
12.16.5 Lifespan Biosciences(US) Recent Development
12.17 Novus Biologicals(US)
12.17.1 Novus Biologicals(US) ENG(Endoglin precursor) Corporation Information
12.17.2 Novus Biologicals(US) ENG(Endoglin precursor) Business Overview and Total Revenue
12.17.3 Novus Biologicals(US) ENG(Endoglin precursor) Sales, Revenue and Gross Margin (2015-2020)
12.17.4 Novus Biologicals(US) ENG(Endoglin precursor) Products Offered
12.17.5 Novus Biologicals(US) Recent Development
12.18 Proteintech(US)
12.18.1 Proteintech(US) ENG(Endoglin precursor) Corporation Information
12.18.2 Proteintech(US) ENG(Endoglin precursor) Business Overview and Total Revenue
12.18.3 Proteintech(US) ENG(Endoglin precursor) Sales, Revenue and Gross Margin (2015-2020)
12.18.4 Proteintech(US) ENG(Endoglin precursor) Products Offered
12.18.5 Proteintech(US) Recent Development
12.19 ProSci(US)
12.19.1 ProSci(US) ENG(Endoglin precursor) Corporation Information
12.19.2 ProSci(US) ENG(Endoglin precursor) Business Overview and Total Revenue
12.19.3 ProSci(US) ENG(Endoglin precursor) Sales, Revenue and Gross Margin (2015-2020)
12.19.4 ProSci(US) ENG(Endoglin precursor) Products Offered
12.19.5 ProSci(US) Recent Development
12.20 ProteoGenix(France)
12.20.1 ProteoGenix(France) ENG(Endoglin precursor) Corporation Information
12.20.2 ProteoGenix(France) ENG(Endoglin precursor) Business Overview and Total Revenue
12.20.3 ProteoGenix(France) ENG(Endoglin precursor) Sales, Revenue and Gross Margin (2015-2020)
12.20.4 ProteoGenix(France) ENG(Endoglin precursor) Products Offered
12.20.5 ProteoGenix(France) Recent Development
12.21 R&D Systems(US)
12.21.1 R&D Systems(US) ENG(Endoglin precursor) Corporation Information
12.21.2 R&D Systems(US) ENG(Endoglin precursor) Business Overview and Total Revenue
12.21.3 R&D Systems(US) ENG(Endoglin precursor) Sales, Revenue and Gross Margin (2015-2020)
12.21.4 R&D Systems(US) ENG(Endoglin precursor) Products Offered
12.21.5 R&D Systems(US) Recent Development
12.22 Rockland(US)
12.22.1 Rockland(US) ENG(Endoglin precursor) Corporation Information
12.22.2 Rockland(US) ENG(Endoglin precursor) Business Overview and Total Revenue
12.22.3 Rockland(US) ENG(Endoglin precursor) Sales, Revenue and Gross Margin (2015-2020)
12.22.4 Rockland(US) ENG(Endoglin precursor) Products Offered
12.22.5 Rockland(US) Recent Development
12.23 St John’s Laboratory Ltd(UK)
12.23.1 St John’s Laboratory Ltd(UK) ENG(Endoglin precursor) Corporation Information
12.23.2 St John’s Laboratory Ltd(UK) ENG(Endoglin precursor) Business Overview and Total Revenue
12.23.3 St John’s Laboratory Ltd(UK) ENG(Endoglin precursor) Sales, Revenue and Gross Margin (2015-2020)
12.23.4 St John’s Laboratory Ltd(UK) ENG(Endoglin precursor) Products Offered
12.23.5 St John’s Laboratory Ltd(UK) Recent Development
12.24 Stemcell(Canada)
12.24.1 Stemcell(Canada) ENG(Endoglin precursor) Corporation Information
12.24.2 Stemcell(Canada) ENG(Endoglin precursor) Business Overview and Total Revenue
12.24.3 Stemcell(Canada) ENG(Endoglin precursor) Sales, Revenue and Gross Margin (2015-2020)
12.24.4 Stemcell(Canada) ENG(Endoglin precursor) Products Offered
12.24.5 Stemcell(Canada) Recent Development
12.25 Thermo Fisher Scientific(US)
12.25.1 Thermo Fisher Scientific(US) ENG(Endoglin precursor) Corporation Information
12.25.2 Thermo Fisher Scientific(US) ENG(Endoglin precursor) Business Overview and Total Revenue
12.25.3 Thermo Fisher Scientific(US) ENG(Endoglin precursor) Sales, Revenue and Gross Margin (2015-2020)
12.25.4 Thermo Fisher Scientific(US) ENG(Endoglin precursor) Products Offered
12.25.5 Thermo Fisher Scientific(US) Recent Development
12.26 USBiological(US)
12.26.1 USBiological(US) ENG(Endoglin precursor) Corporation Information
12.26.2 USBiological(US) ENG(Endoglin precursor) Business Overview and Total Revenue
12.26.3 USBiological(US) ENG(Endoglin precursor) Sales, Revenue and Gross Margin (2015-2020)
12.26.4 USBiological(US) ENG(Endoglin precursor) Products Offered
12.26.5 USBiological(US) Recent Development
13 ENG(Endoglin precursor) Manufacturing Cost Analysis
13.1 ENG(Endoglin precursor) Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of ENG(Endoglin precursor)
13.4 ENG(Endoglin precursor) Industrial Chain Analysis
14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 ENG(Endoglin precursor) Distributors List
14.3 ENG(Endoglin precursor) Customers
15 Market Dynamics
15.1 Market Trends
15.2 Opportunities and Drivers
15.3 Challenges
15.4 Porter’s Five Forces Analysis
16 Research Findings and Conclusion
17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer
Table 1. Global ENG(Endoglin precursor) Sales (K MT) Growth Rate by Type (2020-2026)
Table 2. Global ENG(Endoglin precursor) Sales (K MT) Comparison by Application (2020-2026)
Table 3. Global Market ENG(Endoglin precursor) Market Size (US$ Million) by Region:2015 VS 2020 &2026
Table 4. Global ENG(Endoglin precursor) Sales (K MT) by Region (2015-2020)
Table 5. Global ENG(Endoglin precursor) Sales Market Share by Region (2015-2020)
Table 6. Global ENG(Endoglin precursor) Revenue (US$ Million) Market Share by Region (2015-2020))
Table 7. Global ENG(Endoglin precursor) Revenue Share by Region (2015-2020)
Table 8. Global ENG(Endoglin precursor) Sales (K MT) Forecast by Region (2021-2026)
Table 9. Global ENG(Endoglin precursor) Sales Market Share Forecast by Region (2021-2026)
Table 10. Global ENG(Endoglin precursor) Revenue (US$ Million) Forecast by Region (2021-2026)
Table 11. Global ENG(Endoglin precursor) Revenue Share Forecast by Region (2021-2026)
Table 12. Global ENG(Endoglin precursor) (K MT) of Key Companies (2015-2020)
Table 13. Global ENG(Endoglin precursor) Sales Share by Company (2015-2020)
Table 14. Global ENG(Endoglin precursor) Revenue (US$ Million) by Company (2015-2020)
Table 15. Global ENG(Endoglin precursor) Revenue Share by Company (2015-2020)
Table 16. Global ENG(Endoglin precursor) by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in ENG(Endoglin precursor) as of 2019)
Table 17. Global ENG(Endoglin precursor) Average Price (USD/MT) of Key Company (2015-2020)
Table 18. Manufacturers ENG(Endoglin precursor) Manufacturing Sites and Area Served
Table 19. Manufacturers ENG(Endoglin precursor) Product Type
Table 20. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 21. Main Points Interviewed from Key ENG(Endoglin precursor) Players
Table 22. Global ENG(Endoglin precursor) Sales (K MT) by Type (2015-2020)
Table 23. Global ENG(Endoglin precursor) Sales Share by Type (2015-2020)
Table 24. Global ENG(Endoglin precursor) Revenue (US$ Million) Market Share by Type (2015-2020)
Table 25. Global ENG(Endoglin precursor) Price (K MT) by Type (2015-2020)
Table 26. Global ENG(Endoglin precursor) Sales Share by Type (2021-2026)
Table 27. Global ENG(Endoglin precursor) Revenue (US$ Million) Market Share by Type (2021-2026)
Table 28. Global ENG(Endoglin precursor) Revenue Share by Type (2021-2026)
Table 29. Global ENG(Endoglin precursor) Price (K MT) by Type (2021-2026)
Table 30. Global ENG(Endoglin precursor) Sales (K MT) by Application (2015-2020)
Table 31. Global ENG(Endoglin precursor) Sales Share by Application (2015-2020)
Table 32. Global ENG(Endoglin precursor) Revenue (US$ Million) Market Share by Application (2015-2020)
Table 33. Global ENG(Endoglin precursor) Price (K MT) by Application (2015-2020)
Table 34. Global ENG(Endoglin precursor) Sales (K MT) by Application (2021-2026)
Table 35. Global ENG(Endoglin precursor) Sales Share by Application (2021-2026)
Table 36. Global ENG(Endoglin precursor) Revenue (US$ Million) Market Share by Application (2021-2026)
Table 37. Global ENG(Endoglin precursor) Revenue Share by Application (2021-2026)
Table 38. Global ENG(Endoglin precursor) Price (K MT) by Application (2021-2026)
Table 39. United States ENG(Endoglin precursor) Sales (K MT) by Company (2015-2020)
Table 40. United States ENG(Endoglin precursor) Sales Market Share by Company (2015-2020)
Table 41. United States ENG(Endoglin precursor) Sales (K MT) by Type (2015-2020)
Table 42. United States ENG(Endoglin precursor) Sales Market Share by Type (2015-2020)
Table 43. United States ENG(Endoglin precursor) Sales (K MT) by Application (2015-2020)
Table 44. United States ENG(Endoglin precursor) Sales Market Share by Application (2015-2020)
Table 45. Europe ENG(Endoglin precursor) Sales (K MT) by Company (2015-2020)
Table 46. Europe ENG(Endoglin precursor) Sales Market Share by Company (2015-2020)
Table 47. Europe ENG(Endoglin precursor) Sales (K MT) by Type (2015-2020)
Table 48. Europe ENG(Endoglin precursor) Sales Market Share by Type (2015-2020)
Table 49. Europe ENG(Endoglin precursor) Sales (K MT) by Application (2015-2020)
Table 50. Europe ENG(Endoglin precursor) Sales Market Share by Type (2015-2020)
Table 51. China ENG(Endoglin precursor) Sales (K MT) by Company (2015-2020)
Table 52. China ENG(Endoglin precursor) Sales Market Share by Company (2015-2020)
Table 53. China ENG(Endoglin precursor) Sales (K MT) by Type (2015-2020)
Table 54. China ENG(Endoglin precursor) Sales Market Share by Type (2015-2020)
Table 55. China ENG(Endoglin precursor) Sales (K MT) by Application (2015-2020)
Table 56. China ENG(Endoglin precursor) Sales Market Share by Application (2015-2020)
Table 57. Japan ENG(Endoglin precursor) Sales (K MT) by Company (2015-2020)
Table 58. Japan ENG(Endoglin precursor) Sales Market Share by Company (2015-2020)
Table 59. Japan ENG(Endoglin precursor) Sales (K MT) by Type (2015-2020)
Table 60. Japan ENG(Endoglin precursor) Sales Market Share by Type (2015-2020)
Table 61. Japan ENG(Endoglin precursor) Sales (K MT) by Application (2015-2020)
Table 62. Japan ENG(Endoglin precursor) Sales Market Share by Application (2015-2020)
Table 63. Southeast Asia ENG(Endoglin precursor) Sales (K MT) by Company (2015-2020)
Table 64. Southeast Asia ENG(Endoglin precursor) Sales Market Share by Company (2015-2020)
Table 65. Southeast Asia ENG(Endoglin precursor) Sales (K MT) by Type (2015-2020)
Table 66. Southeast Asia ENG(Endoglin precursor) Sales Market Share by Type (2015-2020)
Table 67. Southeast Asia ENG(Endoglin precursor) Sales (K MT) by Type (2015-2020)
Table 68. Southeast Asia ENG(Endoglin precursor) Sales Market Share by Application (2015-2020)
Table 69. India ENG(Endoglin precursor) Sales (K MT) by Company (2015-2020)
Table 70. India ENG(Endoglin precursor) Sales Market Share by Company (2015-2020)
Table 71. India ENG(Endoglin precursor) Sales (K MT) by Type (2015-2020)
Table 72. India ENG(Endoglin precursor) Sales Market Share by Type (2015-2020)
Table 73. India ENG(Endoglin precursor) Sales (K MT) by Application (2015-2020)
Table 74. India ENG(Endoglin precursor) Sales Market Share by Application (2015-2020)
Table 75. Aviva Systems Biology Corporation(USA) Corporation Information
Table 76. Aviva Systems Biology Corporation(USA) Description and Business Overview
Table 77. Aviva Systems Biology Corporation(USA) ENG(Endoglin precursor) Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 78. Aviva Systems Biology Corporation(USA) ENG(Endoglin precursor) Product
Table 79. Aviva Systems Biology Corporation(USA) Recent Development
Table 80. Atlas Antibodies(Sweden) Corporation Information
Table 81. Atlas Antibodies(Sweden) Description and Business Overview
Table 82. Atlas Antibodies(Sweden) ENG(Endoglin precursor) Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 83. Atlas Antibodies(Sweden) ENG(Endoglin precursor) Product
Table 84. Atlas Antibodies(Sweden) Recent Development
Table 85. Abbexa Ltd(UK) Corporation Information
Table 86. Abbexa Ltd(UK) Description and Business Overview
Table 87. Abbexa Ltd(UK) ENG(Endoglin precursor) Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 88. Abbexa Ltd(UK) ENG(Endoglin precursor) Product
Table 89. Abbexa Ltd(UK) Recent Development
Table 90. Abiocode(US) Corporation Information
Table 91. Abiocode(US) Description and Business Overview
Table 92. Abiocode(US) ENG(Endoglin precursor) Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 93. Abiocode(US) ENG(Endoglin precursor) Product
Table 94. Abiocode(US) Recent Development
Table 95. Boster Biological Technology(USA) Corporation Information
Table 96. Boster Biological Technology(USA) Description and Business Overview
Table 97. Boster Biological Technology(USA) ENG(Endoglin precursor) Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 98. Boster Biological Technology(USA) ENG(Endoglin precursor) Product
Table 99. Boster Biological Technology(USA) Recent Development
Table 100. Biobyt(UK) Corporation Information
Table 101. Biobyt(UK) Description and Business Overview
Table 102. Biobyt(UK) ENG(Endoglin precursor) Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 103. Biobyt(UK) ENG(Endoglin precursor) Product
Table 104. Biobyt(UK) Recent Development
Table 105. Bio-Rad(US) Corporation Information
Table 106. Bio-Rad(US) Description and Business Overview
Table 107. Bio-Rad(US) ENG(Endoglin precursor) Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 108. Bio-Rad(US) ENG(Endoglin precursor) Product
Table 109. Bio-Rad(US) Recent Development
Table 110. Bioss Antibodies(US) Corporation Information
Table 111. Bioss Antibodies(US) ENG(Endoglin precursor) Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 112. Bioss Antibodies(US) Description and Business Overview
Table 113. Bioss Antibodies(US) ENG(Endoglin precursor) Product
Table 114. Bioss Antibodies(US) Recent Development
Table 115. Biosensis(US) Corporation Information
Table 116. Biosensis(US) ENG(Endoglin precursor) Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 117. Biosensis(US) Description and Business Overview
Table 118. Biosensis(US) ENG(Endoglin precursor) Product
Table 119. Biosensis(US) Recent Development
Table 120. BioLegend(US) Corporation Information
Table 121. BioLegend(US) Description and Business Overview
Table 122. BioLegend(US) ENG(Endoglin precursor) Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 123. BioLegend(US) ENG(Endoglin precursor) Product
Table 124. BioLegend(US) Recent Development
Table 125. BioVision(US) Corporation Information
Table 126. BioVision(US) Description and Business Overview
Table 127. BioVision(US) ENG(Endoglin precursor) Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 128. BioVision(US) ENG(Endoglin precursor) Product
Table 129. BioVision(US) Recent Development
Table 130. BethylLaboratories(US) Corporation Information
Table 131. BethylLaboratories(US) Description and Business Overview
Table 132. BethylLaboratories(US) ENG(Endoglin precursor) Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 133. BethylLaboratories(US) ENG(Endoglin precursor) Product
Table 134. BethylLaboratories(US) Recent Development
Table 135. Epigentek(US) Corporation Information
Table 136. Epigentek(US) Description and Business Overview
Table 137. Epigentek(US) ENG(Endoglin precursor) Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 138. Epigentek(US) ENG(Endoglin precursor) Product
Table 139. Epigentek(US) Recent Development
Table 140. EnzoLifeSciences(Switzerland) Corporation Information
Table 141. EnzoLifeSciences(Switzerland) Description and Business Overview
Table 142. EnzoLifeSciences(Switzerland) ENG(Endoglin precursor) Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 143. EnzoLifeSciences(Switzerland) ENG(Endoglin precursor) Product
Table 144. EnzoLifeSciences(Switzerland) Recent Development
Table 145. Genetex(US) Corporation Information
Table 146. Genetex(US) Description and Business Overview
Table 147. Genetex(US) ENG(Endoglin precursor) Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 148. Genetex(US) ENG(Endoglin precursor) Product
Table 149. Genetex(US) Recent Development
Table 150. Lifespan Biosciences(US) Corporation Information
Table 151. Lifespan Biosciences(US) Description and Business Overview
Table 152. Lifespan Biosciences(US) ENG(Endoglin precursor) Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 153. Lifespan Biosciences(US) ENG(Endoglin precursor) Product
Table 154. Lifespan Biosciences(US) Recent Development
Table 155. Novus Biologicals(US) Corporation Information
Table 156. Novus Biologicals(US) Description and Business Overview
Table 157. Novus Biologicals(US) ENG(Endoglin precursor) Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 158. Novus Biologicals(US) ENG(Endoglin precursor) Product
Table 159. Novus Biologicals(US) Recent Development
Table 160. Proteintech(US) Corporation Information
Table 161. Proteintech(US) Description and Business Overview
Table 162. Proteintech(US) ENG(Endoglin precursor) Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 163. Proteintech(US) ENG(Endoglin precursor) Product
Table 164. Proteintech(US) Recent Development
Table 165. ProSci(US) Corporation Information
Table 166. ProSci(US) Description and Business Overview
Table 167. ProSci(US) ENG(Endoglin precursor) Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 168. ProSci(US) ENG(Endoglin precursor) Product
Table 169. ProSci(US) Recent Development
Table 170. ProteoGenix(France) Corporation Information
Table 171. ProteoGenix(France) Description and Business Overview
Table 172. ProteoGenix(France) ENG(Endoglin precursor) Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 173. ProteoGenix(France) ENG(Endoglin precursor) Product
Table 174. ProteoGenix(France) Recent Development
Table 175. R&D Systems(US) Corporation Information
Table 176. R&D Systems(US) Description and Business Overview
Table 177. R&D Systems(US) ENG(Endoglin precursor) Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 178. R&D Systems(US) ENG(Endoglin precursor) Product
Table 179. R&D Systems(US) Recent Development
Table 180. Rockland(US) Corporation Information
Table 181. Rockland(US) Description and Business Overview
Table 182. Rockland(US) ENG(Endoglin precursor) Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 183. Rockland(US) ENG(Endoglin precursor) Product
Table 184. Rockland(US) Recent Development
Table 185. St John's Laboratory Ltd(UK) Corporation Information
Table 186. St John's Laboratory Ltd(UK) Description and Business Overview
Table 187. St John's Laboratory Ltd(UK) ENG(Endoglin precursor) Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 188. St John's Laboratory Ltd(UK) ENG(Endoglin precursor) Product
Table 189. St John's Laboratory Ltd(UK) Recent Development
Table 190. Stemcell(Canada) Corporation Information
Table 191. Stemcell(Canada) Description and Business Overview
Table 192. Stemcell(Canada) ENG(Endoglin precursor) Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 193. Stemcell(Canada) ENG(Endoglin precursor) Product
Table 194. Stemcell(Canada) Recent Development
Table 195. Thermo Fisher Scientific(US) Corporation Information
Table 196. Thermo Fisher Scientific(US) Description and Business Overview
Table 197. Thermo Fisher Scientific(US) ENG(Endoglin precursor) Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 198. Thermo Fisher Scientific(US) ENG(Endoglin precursor) Product
Table 199. Thermo Fisher Scientific(US) Recent Development
Table 200. USBiological(US) Corporation Information
Table 201. USBiological(US) Description and Business Overview
Table 202. USBiological(US) ENG(Endoglin precursor) Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 203. USBiological(US) ENG(Endoglin precursor) Product
Table 204. USBiological(US) Recent Development
Table 205. Production Base and Market Concentration Rate of Raw Material
Table 206. Key Suppliers of Raw Materials
Table 207. ENG(Endoglin precursor) Distributors List
Table 208. ENG(Endoglin precursor) Customers List
Table 209. Market Key Trends
Table 210. Key Opportunities and Drivers: Impact Analysis (2020-2026)
Table 211. Key Challenges
Table 212. Research Programs/Design for This Report
Table 213. Key Data Information from Secondary Sources
Table 214. Key Data Information from Primary Sources
List of Figures
Figure 1. ENG(Endoglin precursor) Product Picture
Figure 2. Global ENG(Endoglin precursor) Sales Market Share by Type in 2020 & 2026
Figure 3. Type I Product Picture
Figure 4. Type II Product Picture
Figure 5. Global ENG(Endoglin precursor) Market Share by Application in 2020 & 2026
Figure 6. Biopharmaceutical Companies Examples
Figure 7. Hospitals Examples
Figure 8. Bioscience Research Institutions Examples
Figure 9. Others Examples
Figure 10. Global ENG(Endoglin precursor) Sales (K MT) Growth Rate (2015-2026)
Figure 11. Global ENG(Endoglin precursor) Revenue (US$ Million) Growth Rate (2015-2026)
Figure 12. Global ENG(Endoglin precursor) Price Trends Growth Rate (2015-2026) (USD/MT)
Figure 13. Global ENG(Endoglin precursor) Revenue Market Share by Region: 2015 VS 2020
Figure 14. Global ENG(Endoglin precursor) Revenue Market Share by Region: 2021 VS 2026
Figure 15. United States ENG(Endoglin precursor) Revenue (Million USD) Growth Rate (2015-2026)
Figure 16. United States ENG(Endoglin precursor) Sales (K MT) Growth Rate (2015-2026)
Figure 17. Europe ENG(Endoglin precursor) Revenue (Million USD) Growth Rate (2015-2026)
Figure 18. Europe ENG(Endoglin precursor) Sales (Million USD) Growth Rate (2015-2026)
Figure 19. China ENG(Endoglin precursor) Revenue (Million USD) Growth Rate (2015-2026)
Figure 20. China ENG(Endoglin precursor) Sales (Million USD) and Growth Rate (2015-2026)
Figure 21. Japan ENG(Endoglin precursor) Revenue (Million USD) Growth Rate (2015-2026)
Figure 22. Japan ENG(Endoglin precursor) Sales (Million USD) Growth Rate (2015-2026)
Figure 23. Southeast Asia ENG(Endoglin precursor) Revenue (Million USD) Growth Rate (2015-2026)
Figure 24. Southeast Asia ENG(Endoglin precursor) Sales (Million USD) Growth Rate (2015-2026)
Figure 25. India ENG(Endoglin precursor) Revenue (Million USD) Growth Rate (2015-2026)
Figure 26. India ENG(Endoglin precursor) Sales (Million USD) Growth Rate (2015-2026)
Figure 27. Global 5 Largest ENG(Endoglin precursor) Players Market Share by Revenue in ENG(Endoglin precursor) 2015 & 2019
Figure 28. ENG(Endoglin precursor) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 29. Global ENG(Endoglin precursor) Revenue Share by Type (2015-2020)
Figure 30. Global ENG(Endoglin precursor) Revenue Growth Rate by Type in 2015 & 2019
Figure 31. Global ENG(Endoglin precursor) Revenue Share by Application (2015-2020)
Figure 32. Global ENG(Endoglin precursor) Revenue Growth Rate by Application in 2015 & 2019
Figure 33. United States ENG(Endoglin precursor) Sales Market Share by Type in 2019
Figure 34. United States ENG(Endoglin precursor) Sales Market Share by Type in 2019
Figure 35. Europe ENG(Endoglin precursor) Sales Market Share by Company in 2019
Figure 36. Europe ENG(Endoglin precursor) Sales Market Share by Type in 2019
Figure 37. Europe ENG(Endoglin precursor) Sales Market Share by Application in 2019
Figure 38. China ENG(Endoglin precursor) Sales Market Share by Company in 2019
Figure 39. China ENG(Endoglin precursor) Sales Market Share by Type in 2019
Figure 40. China ENG(Endoglin precursor) Sales Market Share by Application in 2019
Figure 41. Japan ENG(Endoglin precursor) Sales Market Share by Company in 2019
Figure 42. Japan ENG(Endoglin precursor) Sales Market Share by Type in 2019
Figure 43. Japan ENG(Endoglin precursor) Sales Market Share by Application in 2019
Figure 44. Southeast Asia ENG(Endoglin precursor) Sales Market Share by Company in 2019
Figure 45. Southeast Asia ENG(Endoglin precursor) Sales Market Share by Type in 2019
Figure 46. Southeast Asia ENG(Endoglin precursor) Sales Market Share by Application in 2019
Figure 47. India ENG(Endoglin precursor) Sales Market Share by Company in 2019
Figure 48. India ENG(Endoglin precursor) Sales Market Share by Type in 2019
Figure 49. India ENG(Endoglin precursor) Sales Market Share by Application in 2019
Figure 50. Aviva Systems Biology Corporation(USA) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 51. Atlas Antibodies(Sweden) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 52. Abbexa Ltd(UK) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 53. Abiocode(US) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 54. Boster Biological Technology(USA) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 55. Biobyt(UK) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 56. Bio-Rad(US) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 57. Bioss Antibodies(US) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 58. Biosensis(US) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 59. BioLegend(US) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 60. BioVision(US) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 61. BethylLaboratories(US) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 62. Epigentek(US) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 63. EnzoLifeSciences(Switzerland) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 64. Genetex(US) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 65. Lifespan Biosciences(US) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 66. Novus Biologicals(US) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 67. Proteintech(US) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 68. ProSci(US) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 69. ProteoGenix(France) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 70. R&D Systems(US) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 71. Rockland(US) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 72. St John's Laboratory Ltd(UK) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 73. Stemcell(Canada) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 74. Thermo Fisher Scientific(US) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 75. USBiological(US) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 76. Key Raw Materials Price Trend
Figure 77. Manufacturing Cost Structure of ENG(Endoglin precursor)
Figure 78. Manufacturing Process Analysis of ENG(Endoglin precursor)
Figure 79. ENG(Endoglin precursor) Industrial Chain Analysis
Figure 80. Channels of Distribution
Figure 81. Distributors Profiles
Figure 82. Porter's Five Forces Analysis
Figure 83. Bottom-up and Top-down Approaches for This Report
Figure 84. Data Triangulation
Figure 85. Key Executives Interviewed
ENG（エンドグリン前駆体）の世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global ENG(Endoglin precursor) market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The ENG(Endoglin precurso…- STAB2抗体（スタビリン-2前駆体）の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global STAB2 Antibody(Stabilin-2 Precursor) market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The STAB2 An…
- STAB1抗体（スタビリン-1前駆体）の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global STAB1 Antibody(Stabilin-1 Precursor) market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The STAB1 An…
- IL6（インターロイキン-6前駆体）の世界市場レポート2020 Market Analysis and Insights: Global IL6(Interleukin-6 Precursor) Market The global IL6(Interleukin-6 Precursor) market was valued at US$ xx million in 2019 and will reach US$ xx million by the end of 2026, growing at a CAGR of xx% during 2020-2026. Global IL6(Interleukin-6 Precursor) Scope and Mark…
- LAYN抗体（レイリン前駆体）の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global LAYN Antibody(Layilin Precursor) market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The LAYN Antibod…